


Pentostatin

Chemical Properties

CAS No. :	53910-25-1
Formula:	C ₁₁ H ₁₆ N ₄ O ₄
Molecular Weight:	268.27
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



Biological Description

Description	Pentostatin (CI-825) is an extremely effective and irreversible inhibitor of adenosine deaminase (K _i : 2.5 pM).
Targets(IC50)	Antibiotic, Adenosine Receptor, Adenosine Deaminase

Solubility Information

Solubility	DMSO: 145 mg/mL (540.5 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (7.46 mM), Sonication is recommended. 10% DMSO+90% Saline: 10 mg/mL (37.28 mM), Solution. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	3.7276 mL	18.6379 mL	37.2759 mL
5 mM	0.7455 mL	3.7276 mL	7.4552 mL
10 mM	0.3728 mL	1.8638 mL	3.7276 mL
50 mM	0.0746 mL	0.3728 mL	0.7455 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

- Nabhan, et Al. Purine nucleoside analogues and combination therapies in B-cell chronic lymphocytic leukemia: dawn of a new era. *Leukemia Res.* 28 429.
- Wang J, Liu Y, Liu Y, et al. Time-resolved protein activation by proximal decaging in living systems. *Nature.* 2019, 569(7757): 509-513.
- Klohs Klohs WD., et al. Pentostatin: future directions. *Pharmacol.Rev.* 44 459.
- Reynolds C., et al. Richards DA, Robbins GJ, Vellek M, Boehm KA, Zhan F, Asmar L.A Phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia. *Invest New Drugs.* 2012 Jun;30(3):1232-40. Epub 2011 Sep 16.
- Grever MR. Hairy cell leukemia: a successful model for experimental therapeutics--pentostatin and new ideas. *Leuk Lymphoma.* 2011 Jun;52 Suppl 2:25-8.
- Dearden CE, Else M, Catovsky D. Long-term results for pentostatin and cladribine treatment of hairy cell leukemia. *Leuk Lymphoma.* 2011 Jun;52 Suppl 2:21-4.
- Wang J, Liu Y, Liu Y, et al. Time-resolved protein activation by proximal decaging in living systems[J]. *Nature.* 2019 May;569(7757):509-513.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286 E_mail: info@targetmol.com Address: 34 Washington Street, Wellesley Hills, MA 02481